Oxford Nanopore Technologies Valuation

Is OXFY.Y undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OXFY.Y when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OXFY.Y's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OXFY.Y's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OXFY.Y?

Key metric: As OXFY.Y is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for OXFY.Y. This is calculated by dividing OXFY.Y's market cap by their current revenue.
What is OXFY.Y's PS Ratio?
PS Ratio	7.3x
Sales	UK£167.75m
Market Cap	UK£1.23b

OXFY.Y key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.1x
Enterprise Value/EBITDA	-6.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does OXFY.Y's PS Ratio compare to its peers?

The above table shows the PS ratio for OXFY.Y vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.7x
TXG 10x Genomics	2.8x	5.8%	US$1.7b
FTRE Fortrea Holdings	0.6x	2.4%	US$1.8b
BLFS BioLife Solutions	8.2x	11.1%	US$1.2b
AZTA Azenta	3.1x	0.4%	US$2.1b
OXFY.Y Oxford Nanopore Technologies	7.3x	22.6%	US$1.2b

Price-To-Sales vs Peers: OXFY.Y is expensive based on its Price-To-Sales Ratio (7.3x) compared to the peer average (3.7x).

Price to Sales Ratio vs Industry

How does OXFY.Y's PS Ratio compare vs other companies in the US Life Sciences Industry?

10 Companies	Price / Sales	Estimated Growth	Market Cap
FTRE Fortrea Holdings	0.6x	2.4%	US$1.77b
ATLN Atlantic International	0.6x	n/a	US$259.76m
NOTV Inotiv	0.2x	7.5%	US$93.35m
SNCE Science 37 Holdings	0.6x	17.5%	US$34.67m

10 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: OXFY.Y is expensive based on its Price-To-Sales Ratio (7.3x) compared to the US Life Sciences industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is OXFY.Y's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OXFY.Y PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	7.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate OXFY.Y's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

5.3%

17.0%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$56.91

0.6%

9.8%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

4.7%

-4.8%